Janja Pretnar Oblak

Janja Pretnar Oblak

Auto-generated profile, based on publicly available information

Janja Pretnar Oblak

Department of Vascular Neurology and Intensive Neurological Therapy, University Medical Centre Ljubljana , Ljubljana

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2016 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
EGEllen Gelpi
Ellen Gelpi
RHRomana Hoeftberger
Romana Hoeftberger
Francesc GrausFrancesc Graus
Francesc Graus
HLHelen Ling
Helen Ling
JHJanice L. Holton
Janice L. Holton
Gabor G. KovacsGabor G. Kovacs
Gabor G. Kovacs
We recently reported a novel neurological syndrome characterized by a unique NREM and REM parasomnia with sleep apnea and stridor, accompanied by bulbar dysfunction and specific association with antibodies against the neuronal cell-adhesion protein IgLON5. All patients had the HLA-DRB1*1001 and HLA-DQB1*0501 alleles. Neuropathological findings in two patients revealed a novel tauopathy restricted to neurons and predominantly involving the hypothalamus and tegmentum of the brainstem. The aim of the current study is to describe the neuropathological features of the anti-IgLON5 syndrome and to provide diagnostic levels of certainty based on the presence of associated clinical and immunological data. The brains of six patients were examined and the features required for the neuropathological diagnosis were established by consensus. Additional clinical and immunological criteria were used to define “definite”, “probable” and “possible” diagnostic categories. The brains of all patients showed remarkably similar features consistent with a neurodegenerative disease with neuronal loss and gliosis and absence of inflammatory infiltrates. The most relevant finding was the neuronal accumulation of hyperphosphorylated tau composed of both three-repeat (3R) and four-repeat (4R) tau isoforms, preferentially involving the hypothalamus, and more severely the tegmental nuclei of the brainstem with a cranio-caudal gradient of severity until the upper cervical cord. A “definite” diagnosis of anti-IgLON5-related tauopathy is established when these neuropathological features are present along with the detection of serum or CSF IgLON5 antibodies. When the antibody status is unknown, a “probable” diagnosis requires neuropathological findings along with a compatible clinical history or confirmation of possession of HLA-DRB1*1001 and HLA-DQB1*0501 alleles. A “possible” diagnosis should be considered in cases with compatible neuropathology but without information about a relevant clinical presentation and immunological status. These criteria should help to identify undiagnosed cases among archival tissue, and will assist future clinicopathological studies of this novel disorder.

1 October 2006 in Stroke
Verified
Journal Article
Closed access
JPJanja Pretnar-Oblak
Janja Pretnar-Oblak
MSMiso Sabovic
Miso Sabovic
MSMiran Sebestjen
Miran Sebestjen
TPTomaz Pogacnik
Tomaz Pogacnik
MZMarjan Zaletel
Marjan Zaletel
Background and Purpose— In our study we hypothesized that statins improve endothelial function in patients with lacunar infarctions (LI). Cerebral and systemic endothelial function was determined before and after 3-months treatment with atorvastatin. Methods— Cerebral endothelial function was determined by l -arginine reactivity and systemic endothelial function by flow-mediated dilatation (FMD) in patients with LI (18 patients, aged 61.1±7.6 years), 20 age- and gender-matched patients with similar risk factors (SR) and 19 age- and gender-matched healthy controls. The mean arterial velocity (v m ) in both middle cerebral arteries was measured by transcranial Doppler sonography before, during and after a 30-minute intravenous infusion of l -arginine. FMD of the brachial artery after hyperaemia was determined. The measurements were repeated after 3-months treatment with 40 mg of atorvastatin per day. Results— l -arginine reactivity was decreased in LI patients (13.1±8.4%) and in patients with SR compared with healthy controls ( P ≤0.01). FMD was more impaired in patients with LI (0.06±4.9%) compared with patients with SR and healthy controls ( P ≤0.01). After atorvastatin treatment, l -arginine reactivity and FMD improved in both patients with LI (17.1±7.6%; 7.0±5.7%) and patients with SR ( P ≤0.01). Previously mildly increased cholesterol values normalized. Conclusion— The decreased l -arginine reactivity and FMD improve after atorvastatin treatment in both patients with LI and patients with SR.

9 February 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
BMBranko Malojcic
Branko Malojcic
PGPanteleimon Giannakopoulos
Panteleimon Giannakopoulos
FSFarzaneh A. Sorond
Farzaneh A. Sorond
Elsa AzevedoElsa Azevedo
Elsa Azevedo
MDMarina Diomedi
Marina Diomedi
BRBernhard Rosengarten
Bernhard Rosengarten
The vascular contributions to neurodegeneration and neuroinflammation may be assessed by magnetic resonance imaging (MRI) and ultrasonography (US). This review summarises the methodology for these widely available, safe and relatively low cost tools and analyses recent work highlighting their potential utility as biomarkers for differentiating subtypes of cognitive impairment and dementia, tracking disease progression and evaluating response to treatment in various neurocognitive disorders. At the 9th International Congress on Vascular Dementia (Ljubljana, Slovenia, October 2015) a writing group of experts was formed to review the evidence on the utility of US and arterial spin labelling (ASL) as neurophysiological markers of normal ageing, vascular cognitive impairment (VCI) and Alzheimer’s disease (AD). Original articles, systematic literature reviews, guidelines and expert opinions published until September 2016 were critically analysed to summarise existing evidence, indicate gaps in current knowledge and, when appropriate, suggest standards of use for the most widely used US and ASL applications. Cerebral hypoperfusion has been linked to cognitive decline either as a risk or an aggravating factor. Hypoperfusion as a consequence of microangiopathy, macroangiopathy or cardiac dysfunction can promote or accelerate neurodegeneration, blood-brain barrier disruption and neuroinflammation. US can evaluate the cerebrovascular tree for pathological structure and functional changes contributing to cerebral hypoperfusion. Microvascular pathology and hypoperfusion at the level of capillaries and small arterioles can also be assessed by ASL, an MRI signal. Despite increasing evidence supporting the utility of these methods in detection of microvascular pathology, cerebral hypoperfusion, neurovascular unit dysfunction and, most importantly, disease progression, incomplete standardisation and missing validated cut-off values limit their use in daily routine. US and ASL are promising tools with excellent temporal resolution, which will have a significant impact on our understanding of the vascular contributions to VCI and AD and may also be relevant for assessing future prevention and therapeutic strategies for these conditions. Our work provides recommendations regarding the use of non-invasive imaging techniques to investigate the functional consequences of vascular burden in dementia.

6 December 2005
Verified
Journal Article
Closed access
MZMarjan Zaletel
Marjan Zaletel
MSMartin Strucl
Martin Strucl
JPJanja Pretnar-Oblak
Janja Pretnar-Oblak
BZBojana Zvan
Bojana Zvan

4 January 2011 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
DPD. Perko
D. Perko
JPJ. Pretnar-Oblak
J. Pretnar-Oblak
MŠM. Šabovič
M. Šabovič
BŽB. Žvan
B. Žvan
MZM. Zaletel
M. Zaletel
OBJECTIVE - Cerebral infarction preferentially affects the posterior cerebral artery distribution in migraine patients. The results obtained from the few known studies that have compared the anterior and posterior cerebral endothelial function are contradictory. To the best of our knowledge, cerebrovascular reactivity to L-arginine (CVR), measured by transcranial Doppler sonography (TCD), has not been previously used to determine the posterior cerebral endothelial function in migraine patients with (MwA) and without aura (MwoA). MATERIALS AND METHODS - Forty migraine patients without comorbidities (20 MwA, 20 MwoA) and 20 healthy subjects were included. By employing strict inclusion criteria, we avoided the possible vascular risk factors. Mean arterial velocity in the middle cerebral artery (MCA) and the posterior cerebral artery (PCA) was measured by TCD before and after infusion of L-arginine, and CVR to L-arginine was then calculated. RESULTS - All migraine patients had lower CVR to L-arginine in PCA (P = 0.002) and similar in MCA (P = 0.29) compared to healthy subjects. This difference was also present in MwA and MwoA compared to healthy subjects (P = 0.003). CONCLUSIONS - Lower CVR to L-arginine in PCA in migraine patients could associate migraine and cerebral infarcts that are more common in the posterior cerebral artery distribution.

29 September 2023 in International Journal of Stroke
Verified
Journal Article
Closed access
SPSlaven Pikija
Slaven Pikija
JPJanja Pretnar-Oblak
Janja Pretnar-Oblak
SFSenta Frol
Senta Frol
BMBranko Malojcic
Branko Malojcic
TGThomas Gattringer
Thomas Gattringer
SFSimon Fandler-Höfler
Simon Fandler-Höfler
Background: The transmission of amyloid β (Aβ) in humans leading to iatrogenic cerebral amyloid angiopathy (iCAA) is a novel concept with analogies to prion diseases. However, the number of published cases is low, and larger international studies are missing. Aims: We aimed to build a large multinational collaboration on iCAA to better understand the clinical spectrum of affected patients. Methods: We collected clinical data on patients with iCAA from Austria, Croatia, Italy, Slovenia, and Spain. Patients were included if they met the proposed Queen Square diagnostic criteria (QSC) for iCAA. In addition, we pooled data on disease onset, latency, and cerebrospinal fluid (CSF) biomarkers from previously published iCAA cases based on a systematic literature review. Results: Twenty-seven patients (22% women) were included in this study. Of these, 19 (70%) met the criteria for probable and 8 (30%) for possible iCAA. Prior neurosurgical procedures were performed in all patients (93% brain surgery, 7% spinal surgery) at median age of 8 (interquartile range (IQR) = 4–18, range = 0–26 years) years. The median symptom latency was 39 years (IQR = 34–41, range = 28–49). The median age at symptom onset was 49 years (IQR = 43–55, range = 32–70). Twenty-one patients (78%) presented with intracranial hemorrhage and 3 (11%) with seizures. Conclusions: Our large international case series of patients with iCAA confirms a wide age boundary for the diagnosis of iCAA. Dissemination of awareness of this rare condition will help to identify more affected patients.